These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 12649087)

  • 1. Soluble tissue factor induces coagulation on tumor endothelial cells in vivo if coadministered with low-dose lipopolysaccharides.
    Philipp J; Dienst A; Unruh M; Wagener A; Grunow A; Engert A; Fries JW; Gottstein C
    Arterioscler Thromb Vasc Biol; 2003 May; 23(5):905-10. PubMed ID: 12649087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins.
    Dienst A; Grunow A; Unruh M; Rabausch B; Nör JE; Fries JW; Gottstein C
    J Natl Cancer Inst; 2005 May; 97(10):733-47. PubMed ID: 15900043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature.
    Kessler T; Bieker R; Padró T; Schwöppe C; Persigehl T; Bremer C; Kreuter M; Berdel WE; Mesters RM
    Clin Cancer Res; 2005 Sep; 11(17):6317-24. PubMed ID: 16144936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
    Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
    Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.
    Curnis F; Sacchi A; Corti A
    J Clin Invest; 2002 Aug; 110(4):475-82. PubMed ID: 12189241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
    Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
    Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
    Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
    Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
    Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature.
    Ran S; Gao B; Duffy S; Watkins L; Rote N; Thorpe PE
    Cancer Res; 1998 Oct; 58(20):4646-53. PubMed ID: 9788617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
    Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.
    Mortara L; Balza E; Sassi F; Castellani P; Carnemolla B; De Lerma Barbaro A; Fossati S; Tosi G; Accolla RS; Borsi L
    Eur J Immunol; 2007 Dec; 37(12):3381-92. PubMed ID: 18022863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A selective tumor microvasculature thrombogen that targets a novel receptor complex in the tumor angiogenic microenvironment.
    El-Sheikh A; Borgstrom P; Bhattacharjee G; Belting M; Edgington TS
    Cancer Res; 2005 Dec; 65(23):11109-17. PubMed ID: 16322261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination immunotherapy of cancer in a mouse model: synergism between tumor necrosis factor and other defense systems.
    Chun M; Hoffmann MK
    Cancer Res; 1987 Jan; 47(1):115-8. PubMed ID: 3791198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
    Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2.
    Oh HK; Ha JM; O E; Lee BH; Lee SK; Shim BS; Hong YK; Joe YA
    Cancer Res; 2007 May; 67(10):4851-9. PubMed ID: 17510415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.
    Ricker JL; Chen Z; Yang XP; Pribluda VS; Swartz GM; Van Waes C
    Clin Cancer Res; 2004 Dec; 10(24):8665-73. PubMed ID: 15623651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.